Compare · BSX vs ZIMV
BSX vs ZIMV
Side-by-side comparison of Boston Scientific Corporation (BSX) and ZimVie Inc. (ZIMV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and ZIMV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $63.97B.
- BSX has hit the wire 4 times in the past 4 weeks while ZIMV has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 9 for ZIMV).
- Company
- Boston Scientific Corporation
- ZimVie Inc.
- Price
- $44.38+0.50%
- $18.99+0.00%
- Market cap
- $63.97B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 9
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
ZimVie Inc.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest ZIMV
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.
- SEC Form 15-12G filed by ZimVie Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by ZimVie Inc.
- Amendment: SEC Form 25-NSE/A filed by ZimVie Inc.
- Officer Kanaglekar Indraneel returned 63,438 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Crawford Sally returned 40,127 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Officer Schneider Sandra returned 40,794 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Asar Vinit K
- Officer Kidwell Heather returned 83,674 shares to the company, closing all direct ownership in the company (SEC Form 4)